Genmab — December 2017
-
Ja, der er ikke mange grunde til at købe Genmab. Det er et biotekselskab uden pipeline og et pharmaselskab uden omsætning
-
...og så kunne man jo sige, jamen er det ikke nu man skal vælge entry - men valuation ligger lige omkring de usd 10b, så der er stadig masser af downside
-
-
-
interesting to read some of these job openings, this one will be " employed at the NKI (The Netherlands Cancer Institute (NKI), Amsterdam)
but regular visits to and meetings with Genmab will ensure sufficient cohesion and momentum." http://www.genmab.com/careers/current-vacancies/vacancy-list-details?id=f4d0c280-f716-61f4-a1a3-ff0000de49ab&lid=bbefdb4b-5fce-4da1-91bc-498689ff9464 -
Her er 4 vinderaktier i 2018 ifølge "eksperterne" https://finans.dk/investor/ECE10155237/eksperterne-har-talt-her-graver-du-dansk-aktieguld-op-i-2018
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind